Oscotec Inc. (KOSDAQ:039200)
South Korea · Delayed Price · Currency is KRW 34,800
-250 (-0.71%)
Sep 9, 2026, 3:30 PM KST
Oscotec Revenue
Oscotec had revenue of 52.65B KRW in the quarter ending June 30, 2026, with 425.61% growth. This brings the company's revenue in the last twelve months to 144.18B, up 232.64% year-over-year. In the year 2025, Oscotec had annual revenue of 99.84B with 193.58% growth.
Revenue (ttm)
144.18B
Revenue Growth
+232.64%
P/S Ratio
9.23
Revenue / Employee
2.53B
Employees
57
Market Cap
1.33T
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 99.84B | 65.83B | 193.58% |
| Dec 31, 2024 | 34.01B | 29.06B | 586.89% |
| Dec 31, 2023 | 4.95B | -111.45M | -2.20% |
| Dec 31, 2022 | 5.06B | 1.16B | 29.71% |
| Dec 31, 2021 | 3.90B | -39.57B | -91.02% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| DongKook Pharmaceutical | 979.60B |
| Huons Global | 846.78B |
| PharmaResearch | 603.58B |
| ST Pharm | 386.46B |
| Sam Chun Dang Pharm. | 259.90B |
| BINEX | 157.28B |
| CG Invites | 30.11B |
| Mezzion Pharma | 8.43B |
Oscotec News
- 3 months ago - Agios Enters Global License Agreement For Cevidoplenib - Nasdaq